Dr Gerard van Odijk

Chair

Drs. Gerard WM van Odijk has an over 25 years track record in the health care industry. From 2006 until the middle of 2012 he has served as President and CEO of Teva Pharmaceuticals Europe. In which role he has been deeply involved in the many successful acquisitions of Teva. He obtained his medical degree from Utrecht University. Following his academic degree, he has held various international executive position and a senior position in GlaxoSmithKline (GSK). Since 2013 he is an independent healthcare industrial advisor. Gerard currently serves as Chairman of the Board for Bavarian Nordic A/S.  He also is Chairman of the Board of Curaeos bv and until recently  Chairman of HTL-Strefa S.A. Before this Gerard has been chairman of Merus n.v. and Syntarga bv. He also served as Non-Executive Board member on the Board of UDG Healthcare plc, Neurogen A/S  and Alvogen Sárl. He is member of the advisory board of the Dutch Medicine Agency.

October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more
July 09, 2019 ‘Het gaat alleen sneller als er geld bij ko... Hubrecht Organoid Technology, kortweg HUB, is als start-up ontstaan op de Uithof, de universiteitscampus in Utrecht. Het... read more